Filing Flows › Comparisons › BBIO vs PBH
BridgeBio Pharma vs Prestige Consumer Healthcare: BBIO and PBH compared
BridgeBio Pharma is the larger company: $353M of revenue in its latest quarter (Q3 2026) against $336M for Prestige Consumer Healthcare (Q2 FY27). BridgeBio Pharma is growing faster (+193% against +23% a year earlier). Prestige Consumer Healthcare is more profitable, with an operating margin of 24.0% against -3.3%.
Where the money goes: BBIO and PBH
BridgeBio Pharma (BBIO) · Q3 2026
BridgeBio Pharma, Q3 2026: revenue $353M (+193% year over year), operating margin -3.3%, net loss $60.5M, operating cash flow −$44.2M. The chart follows the revenue to costs, profit and cash.
Prestige Consumer Healthcare (PBH) · Q2 FY27
Prestige Consumer Healthcare, Q2 FY27: revenue $336M (+23% year over year), operating margin 24.0%, net earnings $25.3M, operating cash flow $37.9M. The chart follows the revenue to costs, profit and cash.
| BridgeBio Pharma (BBIO) | Prestige Consumer Healthcare (PBH) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q2 FY27 |
| Revenue | $353M | $336M |
| Revenue growth, Y/Y | +193% | +23% |
| Gross margin | — | 51.3% |
| Operating margin | -3.3% | 24.0% |
| Net earnings | −$60.5M | $25.3M |
| Net margin | -17.1% | 7.5% |
| Operating cash flow | −$44.2M | $37.9M |
| Free cash flow | — | $34.2M |
| Market value | $14.6B | $2.3B |
| P/E | — | 13.6× |
| Analysts’ mean target | $106.85 | $66.60 |
Where the revenue comes from
BridgeBio Pharma
- Net product revenue: $253M (72%)
- License and services revenue: $79.3M (22%)
- Royalty revenue: $20.5M (6%)
Prestige Consumer Healthcare
- Gastrointestinal: $63.1M (19%)
- Women's Health: $53.6M (16%)
- Wellness, Sleep & Other: $47.3M (14%)
- Dermatologicals: $43.9M (13%)
Questions
Which is bigger, BridgeBio Pharma or Prestige Consumer Healthcare?
BridgeBio Pharma is the larger company: $353M of revenue in its latest quarter (Q3 2026) against $336M for Prestige Consumer Healthcare (Q2 FY27).
Is BridgeBio Pharma or Prestige Consumer Healthcare growing faster?
BridgeBio Pharma is growing faster (+193% against +23% a year earlier).
Which is more profitable, BridgeBio Pharma or Prestige Consumer Healthcare?
Prestige Consumer Healthcare is more profitable, with an operating margin of 24.0% against -3.3%.
More: BridgeBio Pharma earnings · how BridgeBio Pharma makes money · Prestige Consumer Healthcare earnings · how Prestige Consumer Healthcare makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Oct 29, 2026; 10-Q filed Nov 5, 2026). Fiscal quarters can end on different dates. Not investment advice.